Vir Biotechnology
Vir Biotechnology is a biotech company headquartered in San Francisco, CA, specializing in the development of treatments for infectious diseases using advanced platforms like monoclonal antibodies and T cell-based viral vectors.
Services
Vir Biotechnology utilizes a proprietary monoclonal antibody platform for drug discovery and development. The company operates a T cell-based viral vector platform, which holds potential applications in both infectious diseases and oncology. Vir Biotechnology leverages artificial intelligence in its antibody optimization and engineering processes to enhance the effectiveness of its treatment options.
Products
Vir Biotechnology has developed two commercial medicines. Sotrovimab is designed for the treatment of COVID-19, and ansuvimab-zykl is used for the treatment of Ebola. These products represent the company's commitment to addressing some of the most pressing infectious diseases through innovative therapeutic solutions.
Collaborations
Vir Biotechnology engages in collaborations with renowned institutions and leading researchers to advance scientific discoveries. These partnerships enhance the company's capabilities in developing groundbreaking treatments and furthering its research in infectious diseases and other therapeutic areas.
Locations
Vir Biotechnology is headquartered in San Francisco, CA. The company also operates additional locations in Portland, OR, and Bellinzona, Switzerland. These strategic locations support its global research and development activities and facilitate collaboration with international partners.
Research Focus
Vir Biotechnology focuses on developing treatments for infectious diseases. The company’s pipeline includes multiple clinical-stage and preclinical candidates targeting diseases with significant unmet patient needs, such as chronic hepatitis B and D, influenza, and COVID-19. This focus underscores Vir Biotechnology's commitment to improving global healthcare outcomes through science and innovation.